The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Roche
Consulting or Advisory Role - AstraZeneca Spain; Eisai; Lilly; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Pfizer; Pierre Fabre; Roche/Genentech; Tesaro
Travel, Accommodations, Expenses - Celgene; Celgene; Pfizer; Roche
Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.
 
Aranzazu Fernandez-Martinez
No Relationships to Disclose
 
Maki Tanioka
No Relationships to Disclose
 
Cheng Fan
No Relationships to Disclose
 
Joel S. Parker
No Relationships to Disclose
 
Katherine A. Hoadley
No Relationships to Disclose
 
Ian E. Krop
Employment - AMAG Pharmaceuticals (I)
Leadership - AMAG Pharmaceuticals (I)
Stock and Other Ownership Interests - AMAG Pharmaceuticals (I)
Honoraria - Genentech/Roche
Consulting or Advisory Role - Context Therapeutics; Daiichi Sankyo; Genentech/Roche; Macrogenics; Seagen; Taiho Pharmaceutical
Research Funding - Genentech (Inst); Pfizer (Inst)
 
Javier Cortes
Stock and Other Ownership Interests - MedSIR
Honoraria - Celgene; Eisai; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Biothera; Celgene; Cellestia Biotech; Daiichi Sankyo; ERYTECH Pharma; Merus; Polyphor; Roche; Seagen
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Pique (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Eisai; Novartis; Pfizer; Roche
 
Antonio Llombart Cussac
No Relationships to Disclose
 
Paolo Nuciforo
No Relationships to Disclose
 
Patricia Galván
No Relationships to Disclose
 
Tomas Pascual
No Relationships to Disclose
 
Ann H. Partridge
No Relationships to Disclose
 
Aleix Prat
Employment - Novartis (I)
Honoraria - Daiichi Sankyo; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; NanoString Technologies (Inst); Novartis; Pfizer; Roche
Research Funding - Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics
 
Lisa A. Carey
Research Funding - Immunomedics (Inst); Innocrin Pharma (Inst); Syndax (Inst)
Patents, Royalties, Other Intellectual Property - Royalty-sharing agreement, investorship interest in licensed IP to startup company, Falcon Therapeutics, that is designing neural stem cell-based therapy for glioblastoma multiforme. (I)
 
Charles M. Perou
Leadership - Bioclassifier; GeneCentric
Stock and Other Ownership Interests - Bioclassifier; GeneCentric
Consulting or Advisory Role - Bioclassifier; G1 Therapeutics; GeneCentric; Ions Pharmaceuticals
Patents, Royalties, Other Intellectual Property - royalties from PAM50 breast cancer gene patent application, and from lung gene signature patent
Travel, Accommodations, Expenses - Chugai Pharma; Takeda